Anika Therapeutics Q3 2024 Adj EPS $(0.25) Misses $(0.01) Estimate, Sales $38.75M Miss $42.08M Estimate
Portfolio Pulse from Benzinga Newsdesk
Anika Therapeutics reported a Q3 2024 adjusted EPS of $(0.25), missing the consensus estimate of $(0.01) by a significant margin. Sales were $38.75M, also below the expected $42.08M, marking a 6.54% decrease from the previous year.
October 31, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Anika Therapeutics reported a significant earnings miss for Q3 2024, with an adjusted EPS of $(0.25) compared to the expected $(0.01). Sales also fell short at $38.75M, below the $42.08M estimate, and decreased by 6.54% from last year.
The significant miss on both EPS and sales compared to analyst estimates is likely to negatively impact Anika Therapeutics' stock price in the short term. The 2400% miss on EPS and the 7.91% miss on sales indicate potential operational challenges or market conditions affecting the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100